PL1701978T3 - Zastosowanie rozpuszczalnej kadheryny T do leczenia zaburzeń metabolicznych - Google Patents

Zastosowanie rozpuszczalnej kadheryny T do leczenia zaburzeń metabolicznych

Info

Publication number
PL1701978T3
PL1701978T3 PL04812804T PL04812804T PL1701978T3 PL 1701978 T3 PL1701978 T3 PL 1701978T3 PL 04812804 T PL04812804 T PL 04812804T PL 04812804 T PL04812804 T PL 04812804T PL 1701978 T3 PL1701978 T3 PL 1701978T3
Authority
PL
Poland
Prior art keywords
disorder
cadherin
metabolic disorders
soluble
treatment
Prior art date
Application number
PL04812804T
Other languages
English (en)
Inventor
Christopher Hug
Harvey F Lodish
Original Assignee
Whitehead Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Inst Biomedical Res filed Critical Whitehead Inst Biomedical Res
Publication of PL1701978T3 publication Critical patent/PL1701978T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
PL04812804T 2003-12-03 2004-12-02 Zastosowanie rozpuszczalnej kadheryny T do leczenia zaburzeń metabolicznych PL1701978T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52695603P 2003-12-03 2003-12-03
EP04812804A EP1701978B1 (en) 2003-12-03 2004-12-02 Use of soluble T-Cadherin for the treatment of metabolic disorders
PCT/US2004/040363 WO2005057222A2 (en) 2003-12-03 2004-12-02 Use of t-cadherin as a target

Publications (1)

Publication Number Publication Date
PL1701978T3 true PL1701978T3 (pl) 2009-07-31

Family

ID=34676687

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04812804T PL1701978T3 (pl) 2003-12-03 2004-12-02 Zastosowanie rozpuszczalnej kadheryny T do leczenia zaburzeń metabolicznych

Country Status (18)

Country Link
US (1) US20070212686A1 (pl)
EP (1) EP1701978B1 (pl)
JP (1) JP2007519894A (pl)
AT (1) ATE422506T1 (pl)
AU (1) AU2004297914A1 (pl)
CA (1) CA2546126A1 (pl)
CY (1) CY1109014T1 (pl)
DE (1) DE602004019451D1 (pl)
DK (1) DK1701978T3 (pl)
ES (1) ES2320139T3 (pl)
HR (1) HRP20090119T3 (pl)
IL (1) IL175862A (pl)
NO (1) NO20062975L (pl)
PL (1) PL1701978T3 (pl)
PT (1) PT1701978E (pl)
RS (1) RS50754B (pl)
SI (1) SI1701978T1 (pl)
WO (1) WO2005057222A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007204730B2 (en) 2006-01-10 2011-11-17 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
CA2757425C (en) 2009-04-01 2015-06-30 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents
AR076041A1 (es) 2009-04-01 2011-05-11 Colgate Palmolive Co Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
US8617523B2 (en) 2009-04-01 2013-12-31 Colgate-Palmolive Company Anti-biofilm carbonate compounds for use in oral care compositions
TWI405565B (zh) 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗-骨質流失及抗-牙周附連喪失之功效
GB201312010D0 (en) * 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
EP4116711A4 (en) * 2020-03-03 2024-04-10 Tatsuya Sawamura Adiponectin quantification method and analysis reagent for use in said method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245048T3 (es) * 1997-10-15 2005-12-16 Pharis Biotec Gmbh Factor de crecimiento derivado de cadherina y su uso.
JP2002513804A (ja) * 1998-05-05 2002-05-14 アドヘレックス テクノロジーズ インコーポレイテッド 非古典的カドヘリン媒介機能を調節するための化合物および方法
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
AU2001232599B2 (en) * 2000-02-18 2006-10-12 Leangene Ab Transgenic animal model for obesity expressing foxc2
WO2002023184A1 (en) * 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
WO2002053726A2 (en) * 2001-01-02 2002-07-11 Hybrigenics Protein-protein interactions in adipocyte cells
EP1627229A2 (en) * 2003-04-29 2006-02-22 Cytos Biotechnology AG Methods and compositions for modulating the interaction between adiponectin and its receptor
WO2005049861A2 (en) * 2003-11-10 2005-06-02 Epigenomics Ag Method for the analysis of gynaecological cell proliferative disorders

Also Published As

Publication number Publication date
ES2320139T3 (es) 2009-05-19
AU2004297914A1 (en) 2005-06-23
SI1701978T1 (sl) 2009-08-31
WO2005057222A3 (en) 2006-02-23
PT1701978E (pt) 2009-03-03
IL175862A (en) 2010-11-30
EP1701978B1 (en) 2009-02-11
DE602004019451D1 (de) 2009-03-26
CY1109014T1 (el) 2014-07-02
DK1701978T3 (da) 2009-04-06
US20070212686A1 (en) 2007-09-13
NO20062975L (no) 2006-06-26
IL175862A0 (en) 2006-10-05
EP1701978A2 (en) 2006-09-20
JP2007519894A (ja) 2007-07-19
RS50754B (sr) 2010-08-31
HRP20090119T3 (en) 2009-04-30
WO2005057222A2 (en) 2005-06-23
CA2546126A1 (en) 2005-06-23
ATE422506T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
CY1109014T1 (el) Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008030706A3 (en) Anti-myostatin antibodies
NO20035526D0 (no) Forbindelser for behandling av metabolske forstyrrelser
DK1928850T3 (da) Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
DE60121096D1 (de) Methode zur Behandlung von Fettsucht anhand eines Neurotensinreceptor-Liganden
UA76838C2 (uk) Сполуки, що модулюють активність ppar, та способи їх одержання
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
MX339420B (es) Compuestos para la modulacion de la actividad de ppar gamma.
DE602005020313D1 (de) Bisaryl-sulfonamide
DK1725234T3 (da) Fremgangsmåder til behandling af lidelser eller sygdomme, der er forbundet med hyperlipidæmi og hyperkolesterolæmi, med minimering af bivirkninger
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
TWI350373B (en) Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
TW200741009A (en) Methods of modulating SMYD3 for treatment of cancer
IL190347A0 (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
AU2003221878A8 (en) G-protein coupled receptor ligands and methods
WO2005112933A3 (en) Substituted organosulfur compounds and methods of using thereof
WO2006116660A3 (en) Methods of inhibiting a gpr23
CR9479A (es) Moduladores canabinoides de tetrahidrotiopirano pirazol
TNSN06263A1 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
HUP0400762A3 (en) Pharmaceutical composition for preventing or treating diabetes
FI20040879A0 (fi) Laitteisto partikkeleiden, kuten lastun ja hakkeen, käsittelemiseksi, esimerkiksi seulomiseksi tai sirottelemiseksi
WO2007050648A3 (en) Use of tumor necrosis factor- receptor p75 for treatment of ischemia-induced neovascularization
HK40059998A (en) Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof